News GSK ends decades-long hiatus in oral antibiotics for UTIs The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.
News Fabhalta is first FDA-approved therapy for rare disease C3G Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.
News J&J adds to IL-23 options in Crohn's after FDA approval J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.
News Alnylam joins three-way contest in ATTR cardiomyopathy Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.
News Kelun-Biotech first to bag TROP2 approval in lung cancer Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.
News EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua, a potential blockbuster.
Market Access Consolidating data strategy for global success: Insights fro... At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.